No photo of Douglas E Vaughan

View Scopus Profile

Douglas E Vaughan

  • 16270 Citations
1986 …2023
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

My primary clinical interest is in adult cardiovascular disease. My practice has focused on the management and treatment of patients with coronary artery disease. I am also interested in the diagnosis and management of arterial thrombosis. My research interests align with these clinical interests. My primary investigative focus is and has been on the mammalian plasminogen activator system and the role this system plays in cardiovascular disease. We apply a multidisciplinary approach in this effort, and utilize molecular and cellular approaches, as well as animal and human studies.

Certifications and Licenses

Cardiovascular Disease
Internal Medicine

Training Experience

1981Internship, Parkland Memorial Hospital
1983Residency, Parkland Memorial Hospital
1987Postdoctoral Fellowship, Harvard Medical School
1987Fellowship, Brigham & Women's Hospital

Education/Academic qualification

MD, University of Texas - Southwestern

… → 1980

Research interests

  • Aging
  • Cardiovascular Diseases
  • Gene Regulation
  • Stem Cells
  • Vascular Biology
  • Blood and Bleeding Disorders (anemia, clotting, etc.)

Fingerprint Dive into the research topics where Douglas E Vaughan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles
Plasminogen Activator Inhibitor 1 Medicine & Life Sciences
Tissue Plasminogen Activator Medicine & Life Sciences
Plasminogen Activators Medicine & Life Sciences
Bradykinin Medicine & Life Sciences
Renin-Angiotensin System Medicine & Life Sciences
Peptidyl-Dipeptidase A Medicine & Life Sciences
Myocardial Infarction Medicine & Life Sciences
Blood Vessels Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2008 2023

Spontaneous cardiac fibrosis in PAI-1-deficient mice and men: A rare mutation informs a common molecular pathophysiology

Burridge, P., Carr, J., Hou, L., Khan, S. S., Shah, S. J., Vaughan, D. E., Winter, D. R. & Flevaris, P. D.

National Heart, Lung, and Blood Institute

4/15/19 → 3/31/23

Project: Research project

Plasminogen Activator Inhibitor 1
Fibrosis
Mutation
Cardiomyopathies
Cardiac Myocytes

The role of plasminogen activator inhibitor -1 (PAI-1) in chronic kidney disease(CKD)-associated cardiac hypertrophy

Vaughan, D. E.

American Heart Association

1/1/19 → 12/31/20

Project: Research project

Plasminogen Activator Inhibitor 1
Cardiomegaly
Chronic Renal Insufficiency
Hypertrophy
Transgenic Mice

PAI-1 and Vascular Senescence

Abdelwahid, E., Eren, M., Ghosh, A. K., Khan, S. S., Shah, S. J., Vaughan, D. E. & Flevaris, P. D.

National Heart, Lung, and Blood Institute

8/1/18 → 7/31/22

Project: Research project

Plasminogen Activator Inhibitor 1
Blood Vessels
Cardiovascular System
Population
Personal Financing

Plasminogen Activator System in Air Pollutants-Induced Cardiovascular Disease

Ghosh, A. K. & Vaughan, D. E.

American Heart Association

7/1/18 → 6/30/20

Project: Research project

Air Pollutants
Plasminogen Activators
Plasminogen Activator Inhibitor 1
Environmental Pollutants
Cardiovascular Diseases

A SPECT_CT Scanner for Preclinical Imaging Studies

Budinger, G. S., Bulun, S. E., Haney, C. R., Larson, A. C., Meade, T. J., Mirkin, C. A., O'Halloran, T. V., Perlman, H. R., Procissi, D., Qin, G., Spies, S. M., Stock, S. R., Stupp, S., Sznajder, J. I., Vaughan, D. E., Woloschak, G. E., Woodruff, T. K. & Zhao, M.

Office of the Director, National Institutes of Health

5/1/14 → 4/30/20

Project: Research project

Research Output 1986 2019

Acetyltransferase p300 inhibitor reverses hypertension-induced cardiac fibrosis

Rai, R., Sun, T., Ramirez, V., Lux, E., Eren, M., Vaughan, D. E. & Ghosh, A. K., Apr 1 2019, In : Journal of Cellular and Molecular Medicine. 23, 4, p. 3026-3031 6 p.

Research output: Contribution to journal › Article

Open Access
Cardiomegaly
Fibrosis
Hypertension
Epigenomics
Myofibroblasts

Glycine supplementation extends lifespan of male and female mice

Miller, R. A., Harrison, D. E., Astle, C. M., Bogue, M. A., Brind, J., Fernandez, E., Flurkey, K., Javors, M., Ladiges, W., Leeuwenburgh, C., Macchiarini, F., Nelson, J., Ryazanov, A. G., Snyder, J., Stearns, T. M., Vaughan, D. E. & Strong, R., Jun 1 2019, In : Aging Cell. 18, 3, e12953.

Research output: Contribution to journal › Article

Open Access
Glycine
Diet
Methionine
Pathology
Inulin

EPIGENETIC TREATMENT APPROACHES TO CARDIOVASCULAR DISEASE

Ghosh, AK. & Vaughan, DE., 2018, Epigenetics in Human Disease. Tollefsbol, T. (ed.). London: Academic Press, Elsevier, p. 607-641

Research output: Chapter in Book/Report/Conference proceeding › Chapter

5 Citations (Scopus)

A novel acetyltransferase p300 inhibitor ameliorates hypertension-associated cardio-renal fibrosis

Rai, R., Verma, S. K., Kim, D., Ramirez, V., Lux, E., Li, C., Sahoo, S., Wilsbacher, L. D., Vaughan, D. E., Quaggin, S. E. & Ghosh, A. K., Nov 2 2017, In : Epigenetics. 12, 11, p. 1004-1013 10 p.

Research output: Contribution to journal › Article

Fibrosis
Hypertension
Kidney
Podocytes
Mesangial Cells
14 Citations (Scopus)

A null mutation in SERPINE1 protects against biological aging in humans

Khan, S. S., Shah, S. J., Klyachko, E., Baldridge, A. S., Eren, M., Place, A. T., Aviv, A., Puterman, E., Lloyd-Jones, D. M., Heiman, M., Miyata, T., Gupta, S., Shapiro, A. D. & Vaughan, D. E., Jan 1 2017, In : Science Advances. 3, 11, eaao1617.

Research output: Contribution to journal › Article

Plasminogen Activators
Amish
Mutation
Cell Aging
Telomere